Trial Profile
Phase 2 Clinical Trial with Ponatinib as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to prior First Line Tyrosine Kinase Inhibitor Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms PONS
- 12 Sep 2023 Status changed from completed to discontinued.
- 26 Aug 2023 Status changed from active, no longer recruiting to completed.
- 15 Jun 2023 Interim results (n = 18) assessing 3 and 12 months data presented at the 28th Congress of the European Haematology Association